HC Wainwright Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $14.00

Sage Therapeutics (NASDAQ:SAGE) had its price target cut by HC Wainwright from $25.00 to $14.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sage Therapeutics’ Q4 2024 earnings at ($1.69) EPS, FY2024 earnings at ($6.72) EPS, Q1 2025 earnings at ($1.54) EPS, Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($4.78) EPS, FY2026 earnings at ($3.63) EPS, FY2027 earnings at ($2.87) EPS and FY2028 earnings at $0.50 EPS.

Other equities research analysts have also recently issued reports about the company. Bank of America cut their price target on Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a research note on Wednesday, October 9th. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday. Raymond James reiterated a “market perform” rating on shares of Sage Therapeutics in a research note on Thursday, October 10th. Truist Financial cut their price target on Sage Therapeutics from $18.00 to $13.00 and set a “hold” rating for the company in a research note on Wednesday, August 14th. Finally, The Goldman Sachs Group cut their price target on Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating for the company in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $12.89.

Sage Therapeutics Stock Down 0.5 %

Shares of NASDAQ:SAGE opened at $6.05 on Wednesday. Sage Therapeutics has a 12-month low of $5.84 and a 12-month high of $28.26. The stock has a market cap of $370.10 million, a PE ratio of -1.08 and a beta of 0.91. The business has a 50 day moving average of $7.44 and a 200-day moving average of $9.95.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The firm had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. During the same quarter in the prior year, the firm earned ($2.81) EPS. The company’s revenue was up 337.1% on a year-over-year basis. Equities research analysts expect that Sage Therapeutics will post -6.43 earnings per share for the current year.

Institutional Trading of Sage Therapeutics

Several institutional investors have recently modified their holdings of SAGE. Vanguard Group Inc. grew its stake in shares of Sage Therapeutics by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 5,319,360 shares of the biopharmaceutical company’s stock worth $115,271,000 after purchasing an additional 111,358 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Sage Therapeutics by 4.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,568 shares of the biopharmaceutical company’s stock worth $723,000 after purchasing an additional 1,693 shares during the last quarter. Inspire Investing LLC grew its stake in shares of Sage Therapeutics by 9.4% in the first quarter. Inspire Investing LLC now owns 19,234 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 1,652 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Sage Therapeutics by 9.0% in the first quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 1,130 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its stake in shares of Sage Therapeutics by 9.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,644 shares of the biopharmaceutical company’s stock worth $312,000 after purchasing an additional 1,480 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.